Considering that systemic upregulation of Nampt-NAD axis may have the susceptibility of atherosclerosis, our present study indicates that hepatocyte Nampt is a better target than systemic Nampt for prevention and treatment of dyslipidemia and fatty liver. The gene discussed is NAMPT; the disease is Hepatic steatosis.